Vancouver, British Columbia – April 19, 2022 – Gandeeva Therapeutics, a precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop novel therapeutics at an accelerated pace, today announced the formation of its Scientific Advisory Board (SAB) comprised of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.
The SAB will work closely with Gandeeva’s leadership team, as the Company advances its AI-enabled atomic-resolution protein-drug interaction platform to accelerate the discovery, design and development of novel precision medicines, including small molecules and biologics.
“We are excited and privileged to have the opportunity to work with this group of leading experts on the development of our platform and pipeline,” said Sriram Subramaniam, Founder and CEO of Gandeeva Therapeutics. “These thought-leaders bring tremendous understanding of structural biology and translational medicine, as well as extensive experience in drug development from discovery to late-stage clinical trials. We look forward to their continued contributions as we advance our pipeline of novel precision therapeutics.”
Members of the Gandeeva Scientific Advisory Board are as follows:
Chas Bountra, Ph.D., Pro-Vice Chancellor for Innovation and Professor of Translational Medicine, Oxford University.
Janet George, Corporate Vice President and General Manager Cloud Enterprise and Artificial Intelligence Solutions Group Intel Corporation.
Martin Gleave, M.D., Director, Vancouver Prostate Centre, and Distinguished Professor and Head, Department of Urologic Sciences, University of British Columbia.
Dermot Kelleher, M.D., Dean, Faculty of Medicine and Vice-President, Health, University of British Columbia.
John Kuriyan, Ph.D., HHMI Investigator, Distinguished Professor of Molecular & Cell Biology and Chemistry, University of California at Berkeley.
Celia Schiffer, Ph.D., Chair and Professor, Biochemistry and Molecular Biotechnology, Director, Institute for Drug Resistance, and Gladys Martin Smith Chair in Oncology, University of Massachusetts Chan Medical School.
Holger Stark, Ph.D., Director, Max-Planck-Institute for Multidisciplinary Sciences, Göttingen.
Philip Tagari, Vice President of Research (Therapeutic Discovery), Amgen Inc.
About Gandeeva Therapeutics, Inc.
Gandeeva™ is a precision biotechnology company harnessing the power of cryo-electron microscopy (cryo-EM) and machine learning to advance drug discovery and development at scale. Gandeeva Founder and CEO, Sriram Subramaniam is recognized internationally for his leadership in driving the cryo-EM resolution revolution and for innovations in 3D electron microscopic imaging. Gandeeva seeks to achieve transformative societal impact on public health by revolutionizing drug discovery and by lowering risks of late-stage clinical failures. Gandeeva is based in Vancouver, Canada. For more information, visit www.gandeeva.com or follow @Gandeeva_Tx on Twitter.